Overview

MsFLASH-01: Escitalopram for Menopausal Symptoms in Midlife Women

Status:
Completed
Trial end date:
2010-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test whether a medication reduces the number, severity and bothersomeness of menopausal hot flashes. Escitalopram (also called Lexapro®) is a selective serotonin reuptake inhibitor (SSRI). It is sold by prescription for depression and general anxiety disorder. An SSRI increases serotonin, a brain substance that is believed to influence mood. Serotonin may also affect brain levels of estradiol, a hormone related to hot flashes. This research study will test whether escitalopram reduces menopausal hot flashes.
Phase:
N/A
Details
Lead Sponsor:
Fred Hutchinson Cancer Research Center
Collaborators:
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
National Center for Complementary and Integrative Health (NCCIH)
National Institute on Aging (NIA)
Office of Research on Women's Health (ORWH)
Treatments:
Citalopram
Dexetimide
Serotonin
Serotonin Uptake Inhibitors